@article{6e3a25257f6b40c8a4f428a237ed8248,
title = "Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)",
abstract = "After publication of the original article [1], the authors identified two errors in the Author details: 1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley's affiliation in addition to Tennessee Oncology. 2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.",
author = "Goldstein, {Lori J.} and Perez, {Raymond P.} and Denise Yardley and Han, {Linda K.} and Reuben, {James M.} and Hui Gao and Susan McCanna and Beth Butler and Ruffini, {Pier Adelchi} and Yi Liu and Rosato, {Roberto R.} and Chang, {Jenny C.}",
note = "Publisher Copyright: {\textcopyright} 2020 BioMed Central Ltd.. All rights reserved.",
year = "2020",
month = may,
day = "20",
doi = "10.1186/s13058-020-01294-7",
language = "English (US)",
volume = "22",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",
}